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1 Abstract 
The translational activity of various unsaturated analogs of L-isoleucine was 
evaluated using an Escherichia coli strain auxotrophic for isoleucine. It was 
observed that the alkene C2-amino-3-methyl-4-pentenoic a id (2)] and alkyne 
C2-amino-3-rnethyl-4-pentynoic acid (3)] derivatives of L-isoleucine can support 
protein synthesis at levels approximately 50% of that observed in cultures 
supplemented with isoleucine. However, no incorporation of the aC or PC 
methylated derivatives could be detected. In order to examine the stereoselectiv- 
ity of incorporation, the (2S, 3s) and (2S, 3R) diastereomers of 2 and 3 were 
prepared. The extents of isoleucine substitution in vivo were 80% and 70% for 
(2S, 3S)-2 and (2S, 3S)-3, respectively, under the conditions examined in this 
study. 
2 Introduction 
The in vivo incorporation into proteins of amino acids analogs bearing non- 
biological chemical reactivity within their side chain would allow a completely 
new chemistry of proteins. For instance, this would have applications in the 
design of new materials by combining proteins to synthetic polymers, nucleic 
acids or carbon hydrates. In the past it was shown that E. coli is extremely 
permissive for the incorporation of artificial amino acids (see ref. 1 for review). 
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Figure 1 Structures of the isoleucine analogs used in this study 
One of the reasons probably lies within the fact that in the course of evolution the 
selection pressure never applied to these amino acid analogs. As the laws 
governing protein structure and function emerge, it is becoming increasingly 
productive to design ‘artificial proteins’ as building blocks for new kinds of 
supra-molecular chemi~ t ry .~ .~  Optimizing such building blocks requires control 
of the driving forces that direct protein folding and assembly. This is achieved 
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largely by controlling the physical and chemical properties of the amino acid side 
chains of the protein of i n t e re~ t .~  In an effort to increase the range of chemical 
function that can be incorporated into proteins, we have focused our investiga- 
tions on the translational activity of unsaturated amino acid analogs because of 
the versatile chemistry of alkenes and alkynes. For example, supramolecular 
structures made up of weakly hydrogen bonded cyclic peptides can be stabilized 
through inter-peptide cross-linking6 utilizing ruthenium-catalyzed ring-closing 
metathesis of pendant alkene  function^.^ We have recently shown that homoal- 
lylglycine and homopropargylglycine can be incorporated in vivo into recom- 
binant proteins.*-' In this paper we examine the incorporation of unsaturated 
isoleucine analogs (Figure 1) into a heterologous protein, mouse dihydrofolate 
reductase (mDHFR), over-expressed in an Escherichia coli host. Analogues 2 and 
3 can be efficiently incorporated into E. coli proteins, and incorporation is 
stereospecific, favoring the (2S, 3s) diastereomers. The results are discussed from 
the standpoint of the insensitivity of the isoleucyl-tRNA synthetase (IleRS) 
editing mechanism to non-canonical amino acids. 
3 Experimental Section 
3.1 Amino Acid Synthesis 
Diastereomers mixtures (Figure 1) of 2-amino-3-methyl-4-pentenoic a id (2), 
2-amino-2-methyl-4-pentynoic acid (21), 2-amino-3-dimethyl-4-pentenoic acid 
(22), 2-amino-2,3-dimethyl-4-pentenoic a id (23), 2-amino-3-methyl-4-pentynoic 
acid (3), 2-amino-3-dimethyl-4-pentynoic acid (31), 2-amino-2,3-dimethyl-4-pen- 
tynoic acid (32) were prepared according to Aidene et al. l 1  The regioselective 
reaction between a-unsaturated organozincs and N-(phenylsulfany1)iminoesters 
was used as a starting step to obtain the a-aminoesters." 
Detailed procedures for the preparation of (2) and (3) pure diastereomers will 
be described elsewhere (Michon et al., manuscript in preparation). 
For all the compounds used, 'H NMR spectra were in agreement with the 
expected structures. 
3.2 Construction of an E. culi Expression Strain 
An E. coli strain (AIV,) that is auxotrophic for valine and isoleucine was 
prepared. The procedure will be described elsewhere (Michon et aE. manuscript 
in preparation). An in vivo test system was designed in order to determine the 
extent of incorporation of isoleucine analogs into an over expressed reporter 
protein. Plasmid pQEl5 (Qiagen) carries a gene encoding mouse dihydrofolate 
reductase (mDHFR) under control of a strong bacteriophage T5 promotor that 
is recognized by E.  coli RNA polymerase. A repressor-binding site has been 
introduced downstream from the T5 promotor on pQE15 that allows a pro- 
grammed induction of DHFR expression by addition of isopropyl-/?-D- 
thiogalactopyranoside (IPTG) to the medium. The gene encoding mDHFR also 
encodes an N-terminal hexahistidine sequence to permit protein purification by 
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immobilized metal affinity chromatography. pQEl5 confers ampiciline resis- 
tance. The auxotrophic E. coli strain AIV, was transformed with pQEl5 to give 
AIVJpQEl 5.12 The repressor plasmid pLys-IQ modified from pLys-S 
(Novagen, Madison, WI, USA) to contain the Ladq  gene encoding the lac 
repressor was then introduced into the AIVJpQE15 strain to give the AN,- 
IQ/pQElS strain. This strain was made in an attempt to prevent ‘leaky’ expres- 
sion of the DHFR gene before induction (see results). This strain was used for all 
the assays. 
3.3 Protein Expression 
To test for analog incorporation 5 mL of M9AA medium supplemented with 
ampicillin (200 pg/mL), chloramphenicol (35 ,ug/mL), 2 mM MgCl,, 100 pM 
CaCl,, 0.2% glucose and 0.5 mg thiamin chloride were inoculated with a single 
colony of AIV,-IQ/pQE15. After overnight growth at 37°C the culture was 
diluted with fresh M9 medium in order to obtain an OD,,, of 0.1. When the 
OD,,, reached 1 (after about 3.5 hours) the cells were sedimented (SOOOg, 10 
min, 4°C) and washed twice with 0.9% NaCl. The cells were resuspended in 50 
mL fresh M9 medium supplemented with the 19 amino acids (16mg/L) but 
lacking isoleucine. Tests tubes containing 10 mL aliquots of this culture were 
prepared and supplemented with 250 ,uL water (negative control), 40 mg/L 
L-isoleucine (2S, 3S/2R, 3R) (positive control), or 80 mg/L of each of the analogs. 
After 10 min of growth DHFR expression was induced by addition of IPTG at a 
final concentration of 0.4 mM. The culture were grown at 37°C for 4 hours and 1 
mL aliquots were spun down. Pellets were suspended in 50 pL of a 10 mM mgC12 
solution containing 5 pg/mL DNAse and 10 pg/mL KNAse. The suspensions 
were frozen, thawed and sonicated prior to electrophoresis. In each case the 
remaining 9 mL were centrifuged and the pellets stored at -20°C overnight 
before DHFR purification. Cellular proteins were resolved by SDS PAGE, and 
mDHFR was detected by western blotting with antibodies raised against the 
histidine tag (Qiagen, Inc., Santa Clarita, CA, USA).12 
3.4 DHFR Purification 
Pellets were thawed for 30 min, and resuspended in 600 pL of buffer (6 M 
guanidine-HCl, 0.1 M NaH,PO,, 0.01 M Tris/HCl, pH 8). The mixture was 
vigorously shaken at room temperature for 1 h. The cell debris was sedimented 
(10 000 g, 30 min at room temperature) and the lysate was submitted to affinity 
chromatography on pre-packed Nickel columns according to the Ni-NTA spin 
column procedure described by Qiagen. The DHFR fractions were recovered in 
a buffer containing 8 M urea, 0.1 M NaH,PO, and 0.01 M Tris/HCl pH 4.5. UV 
spectra of the samples were taken and the amount of DHFR obtained was 
quantified using E = 30500 M-’ cm-l at 280 nm.I3 
3.5 Estimation of the Level of Isoleucine Replacement into DHFR 
Amino acid analysis were obtained from the Beckman Research Institute, Divi- 
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sion of Immunology, City of Hope, Duarte CA. The extent of replacement of 
isoleucine was estimated based on the diminution of isoleucine from its expected 
value. MALDI-TOF spectra were performed on a Voyager-DE STR spec- 
trometer using 3,5-dimethoxy-4-hydroxy-cinnamoic acid as matrix (Mass Spec- 
trometry Center of the Beckman Institute, California Institute of Technology). 
4 Results 
4.1 Analog Incorporation 
Incorporation of selected amino acid analogs into proteins made in vivo has been 
known for many In our study an E. coli strain auxotrophic for 
isoleucine was used to assay the extent of in vivo incorporation of isoleucine 
analogues into mouse dihydrofolate reductase (mDHFR), a test protein readily 
over expressed in bacterial cultures. It was expected that the in vivo incorpor- 
ation of analogs into the proteins would kill the cells (cell lysis). In order to 
estimate the permissivity of E. coli protein biosynthesis, we fed the cells with 
diastereomer mixtures of isoleucine analogs. As shown in Figure 2, mDHFR was 
detected only when the culture medium was supplemented with 2 and 3. It was 
shown earlier that amino acids with bulkier side chains than isoleucine could be 
accommodated in the binding site of the synthetase,17''8 but none of the analogs 
bearing a double methylation on the PC carbon gave detectable amounts of 
mDHFR. 
Among the 20 proteinogenic amino acids, only L-isoleucine and L-threonine 
carry a symmetry center in their side chain and only (2S, 3S)-isoleucine and (2S, 
3R)-threonine are found in proteins. When L-isoleucine was replaced in the 
culture medium by L-alloisoleucine, the (2S, 3R)-1 diastereomer of isoleucine, the 
cell growth slowed dramatically, without evidence of cell lysis. As western 
blotting did not show detectable DHFR expression in such cultures, we conclude 
that (2S, 3R)-1 is incorporated into protein slowly if at all under our experimental 
conditions (Figure 3B, lane 5) .  However, small amounts of DHFR could be 
isolated from such culture (ca, 8 %  of the level of expression obtained in media 
supplemented with L-isoleucine, see Table 1). DHFR synthesis was not due to 
leaky expression before induction, as uninduced cells did not produce DHFR in 
media suppletlented with L-isoleucine (Figure 3B, lane 3). Instead it appears that 
Figure 2 Western blot obtained from a SDS PAGE ofE. coli proteins 4 hours after medium 
shift. Amino acids added as indicated at the top of thejigwe. DHFR was detected 
with antibodies raised against the amino terminal hexahistidine tag 
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kDa 
66 - 
56 - 
42 - 
36 - 
27  
1 2 3  4 5  6 7 8 9  
A 
B 
L-lle (2S, 3R)-1 (2S, 3S)-3 (2S, 3R)-3 (2S, 3S)-2 (25, 3R)-2 
Figure 3 (A) SDS PAGE of E. coli proteins 4 hours after medium shift. Lane 1: molecular 
weight standards; 2: no isoleucine added, induction; 3: isoleucine added, no induc- 
tion. Lanes 4 to 9: analogs added as indicated at the bottom of theJigure. (B) 
Autoradiogram of a western blot obtained from the gel above. DHFR was detected 
with antibodies raised against the amino terminal hexahistidine tag 
the host can provide a small pool of L-isoleucine, probably by means of intracel- 
lular proteolysis. 
In order to compare the efficiency of the methyl position carried by PC on the 
incorporation, we prepared pure diastereomers of 2 and 3. 
(2S, 3S)-2 did not support cell growth and was toxic to the host as shown by a 
drop in OD,,, signaling cell lysis. Most importantly, (2S, 3S)-2 supported 
synthesis of DHFR (Figure 3B, lane 8). Approximately 80% of the L-isoleucine in 
DHFR was replaced by the analog, as determined by amino acid analysis (Table 
1). In contrast to (2S, 3s)  the (2S, 3R) analog neither supported cell growth nor 
caused measurable lysis. DHFR could be isolated after induction of cultures 
supplemented with (2S, 3R)-2 (Figure 3B lane 9), but in amounts too low to 
permit estimation of replacement efficiency (Table 1). 
A fraction of 3 enriched with the (2S, 3s) isomer (diastereomeric ratio 8.6/1.4) 
was tested. This fraction did not support growth but instead caused cell lysis 
(Table l), confirming the toxicity of the analog previously reported.” When 
DHFR was expressed in media supplemented with (2S ,  329-3 (Figure 2B lane 6) 
approximately 70% of the isoleucine was replaced by the analog (Table 1). When 
a fraction of 3 enriched in the (2S, 3R) diastereomer (diastereomeric ratio 8.3/1.7) 
was used the amount of DHFR recovered was too low to allow determination of 
the extent of incorporation. 
MALDI-TOF mass spectra were recorded on the purified DHFR samples. 
The difference in mass obtained between native DHFR and its modified forms 
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Table 1 
69 
Incorporation of isoleucine analogs into D H F R  
amino acid YO replacement DHFR Yield" 
PgbL M." AAA" M ALDI-TOFd 
L-isoleucine (2S, 3 s )  29.5 24044 
(2S, 3R)-1 2.4 ND ND ND 
(2S, 3S)-2 16.4 24018 81 86 
(2S, 3R)-2 1.35 ND ND ND 
(2S, 39-3 11 24007 72 70 
(2S, 3R)-3 ND ND ND ND 
"Yield of DHFR after purification from 10 mL culture, as determined by absorption at 280 nm. 
bWhen mass spectra (MALDI-TOF) were recorded, all samples gave amain peak (85 to 95% of the 
signal intensity). The m/z value of this main peak was used to estimate M ,  the average mass of 
DHFR. 
"Extent of replacement of isoleucine as determined by amino acid analy&. 
dExtent of replacement of isoleucine as estimated from the difference in Mn obtained between 
native DHFR and its modified forms. 
were consistent with the % replacement determined by amino acid composition 
(data not shown). 
5 Discussion 
The first critical step in the incorporation of amino acids analogs is their uptake 
from the culture medium; the analog must be transported across the cytoplasmic 
membrane either by the machinery used for the uptake of its natural counterpart 
or by other import machinery. In the case of non polar isoleucine analogs this 
step might not be limiting as isoleucine and other non polar amino acids are 
likely to cross the phospholipids bilayer by simple diffusion. However, the 
leucine-isoleucine-valine (L1V)-binding proteins present at the surface of E.  coli 
reveals great sequence similarity.20 It was recently showed that the specificity of 
these systems might be weak enough to tolerate closely structurally related 
amino acids.2 
In a second step the analog has to be coupled to a tRNA species by an 
aminoacyl-tRNA synthetase and must circumvent the editing pathways that 
normally limit misacylation of tRNAs. The selectivity (s)  of an aminoacyl-tRNA 
synthetase toward an amino acid is defined as the ratio of the rate of editing to 
the rate of activation. It is noteworthy that the Met-tRNA synthetase exhibits a 
very high selectivity towards homocysteine (s = 11000) and norleucine (s = 
1000) which are both biological amino acids present in the In contrast it 
was previously demonstrated in our group that the synthetase is able to mis- 
charge Met-tRNA with at least three unsaturated methionine analog~es. '~~ The
editing mechanism of E.coli isoleucyl-tRNA synthetase (IleRS) has been exten- 
sively s t ~ d i e d . ~ ~ . ~ ~  Its selectivity for natural amino acids is high, ranging from s 
= 6000 for valine to s = 8.5 x lo6 for alanine.22 IleRS possesses two sites: one 
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for the binding of the amino acid prior to its activation through the formation of 
the AMP-AA phosphoester bond; the other, the editing site, for the hydrolysis of 
this bond when amino acids smaller than isoleucine (which easily fit into the 
binding pocket) have been inappropriately a ~ y l a t e d . ~ ~ ? ~ ~  Analogs 2 and 3 tested 
in this study appear to circumvent the editing mechanism of IleRS because they 
are too large to fit into the editing site. Our results show that IleRS is stereoselec- 
tive as only (2S, 3s) isoleucine analogs are incorporated into protein at measur- 
able rate. This is in agreement with previous binding studies which demonstrated 
that L-2 amino-3s-methylhexanoic acid binds to IleRS ( K ,  = 20 mM-') with a 
stronger affinity than its diastereomer L-2 amino-3R-methylhexanoic acid ( K ,  
= 0.6 mM-').' 
Finally, the analog may be edited at the ribosome level. If the editing mechan- 
ism of the aa-tRNA synthetase seems to insure a weak discrimination between 
natural and artificial amino acids one should expect a more efficient discrimina- 
tion at the ribosome level. Studies performed in nitro show that this step is 
probably permissive e n ~ u g h . ~ ~ - ~ '  The misscharged tRNA must avoid discrimi- 
nation by elongation factor Tu (EFTu) (Figure 4). According to this scheme both 
the rate of GTP hydrolysis (k2)  and the rate of the EFTu.GDP complex dissocia- 
tion with the ribosome ( k 3 )  are defined as internal kinetic standard constants 
which do not depend on the presence of any cognate or non-cognate amino 
acid-tRNA. By contrast the dissociation constants between the ribosome and 
either the ternary complex EFTu.GTP.aa-tRNA (governed by k-')  or the aa- 
tRNA after GTP conversion to GDP (governed by k4) depend on the strength of 
the binding between the ribosome and the aa-tRNA (see ref. 31 for review). It is 
likely that the efficiency of transfer of the non-cognate amino acid to the 
on-growing peptidic chain is much lower than in the case of the natural amino 
acid. In the experiments reported here, the medium shift method prevents 
R pep-tRNA 
+ 
EFTv GDP internal kinetic 
J constants \ k /  
ki 
k2 
R + T e, ROT + RO EFTvGDPaa-tRNA 
k-I 
k-1 < k2 for cognate amino acids 
k.1 > k2 for non cognate amino acids 
k c k3 for cognate amino acids 
k > k3 for non cognate amino acids 
aa-tRNA 
Re EFTvGDP 
+ 
R +EFTvGDP 
Figure 4 Minimal mechanism by which aa-RNs are incorporated into nascent protein (see 
discussion for comments). AatRNA, aminoacyl tRNA; EF Tu, elongation factor; 
GTP, guanosine triphosphate; GDP, guanosine diphosphate; R, ribosome; T, ter- 
nary complex (aa-tRNA*GTP*EFTu). Redrawn from Thompson 19M3' 
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competition by Ile and high level of incorporation of the analogs were obtained. 
However, it has been reported that furanomycin, an analogue of isoleucine, is 
readily incorporated into proteins." Interestingly, in spite of large structural 
discrepancies between furanomycin and isoleucine, the equilibrium constant of 
the ternary complex formation (furanomycyl - tRNA*EFTu*GTP) equals that 
for isoleucyl - tRNAeEFTueGTP formation. In the course of evolution nature 
selected editing processes on the basis of naturally occurring amino acids, which 
are present in the cell. This seems to open relatively large possibilities for the 
incorporation of artificial amino acids making use of the natural machinery of 
the cell. 
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